Novo Nordisk stock plunges 23% after CEO change, lowered forecast
Danish drugmaker Novo Nordisk named Mike Doustdar its new CEO and cut full-year guidance due to weaker U.S. sales forecasts for Wegovy and Ozempic. Shares fell 23% Tuesday. The com…
Danish drugmaker Novo Nordisk named Mike Doustdar its new CEO and cut full-year guidance due to weaker U.S. sales forecasts for Wegovy and Ozempic. Shares fell 23% Tuesday. The com…